Guard Therapeutics International AB (GUARD) - Total Liabilities
Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has total liabilities worth Skr15.24 Million SEK (≈ $1.64 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guard Therapeutics International AB - Total Liabilities Trend (2008–2024)
This chart illustrates how Guard Therapeutics International AB's total liabilities have evolved over time, based on quarterly financial data. See Guard Therapeutics International AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Guard Therapeutics International AB Competitors by Total Liabilities
The table below lists competitors of Guard Therapeutics International AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prestal Holdings Ltd
AU:PTL
|
Australia | AU$4.34 Million |
|
Searchlight Resources Inc
V:SCLT
|
Canada | CA$440.99K |
|
Health and Plant Protein Group Ltd
AU:HPP
|
Australia | AU$125.00K |
|
CryptoStar Corp
V:CSTR
|
Canada | CA$2.41 Million |
|
ICZOOM Group Inc. Class A Ordinary Shares
NASDAQ:IZM
|
USA | $25.82 Million |
|
Libas Consumer Products Limited
NSE:LIBAS
|
India | Rs231.48 Million |
|
Mynaric AG
XETRA:M0YN
|
Germany | €168.37 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Guard Therapeutics International AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guard Therapeutics International AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 4.79 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guard Therapeutics International AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guard Therapeutics International AB (2008–2024)
The table below shows the annual total liabilities of Guard Therapeutics International AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr17.77 Million ≈ $1.91 Million |
-3.89% |
| 2023-12-31 | Skr18.49 Million ≈ $1.99 Million |
-26.74% |
| 2022-12-31 | Skr25.24 Million ≈ $2.72 Million |
+72.20% |
| 2021-12-31 | Skr14.66 Million ≈ $1.58 Million |
+27.08% |
| 2020-12-31 | Skr11.54 Million ≈ $1.24 Million |
+4.02% |
| 2019-12-31 | Skr11.09 Million ≈ $1.19 Million |
-63.30% |
| 2018-12-31 | Skr30.21 Million ≈ $3.25 Million |
+158.65% |
| 2017-12-31 | Skr11.68 Million ≈ $1.26 Million |
-3.71% |
| 2016-12-31 | Skr12.13 Million ≈ $1.31 Million |
+34.74% |
| 2015-12-31 | Skr9.00 Million ≈ $968.97K |
+57.61% |
| 2014-12-31 | Skr5.71 Million ≈ $614.81K |
-73.74% |
| 2013-12-31 | Skr21.75 Million ≈ $2.34 Million |
+26.15% |
| 2012-12-31 | Skr17.25 Million ≈ $1.86 Million |
+204.79% |
| 2011-12-31 | Skr5.66 Million ≈ $608.90K |
+549.00% |
| 2010-12-31 | Skr871.82K ≈ $93.82K |
+191.58% |
| 2008-12-31 | Skr299.00K ≈ $32.18K |
-- |
About Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more